RNA-Sequencing Analysis of LNCaP Wildtype (WT) and RB-p53 CRISPR-Cas9 Double Knockout (DKO) Cells Treated with Enzalutamide

To investigate differential gene expression between LNCaP wild type (WT) cells and cells deficient for RB and p53 in the presence of absence of enzalutamide To investigate differential gene expression between LNCaP wild type (WT) cells and cells deficient for RB and p53 (generated using CRISPR-Cas9) in the presence of absence of enzalutamide We then performed gene expression profiling analysis using data obtained from RNA-seq of both cell lines in 2 different treatment conditions.